Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.70 |
| ▸ | LMNA | P02545 | 7/20 | 0.58 |
| ▸ | SMN1; SMN2 | Q16637 | 6/20 | 0.58 |
| ▸ | HTT | P42858 | 5/20 | 0.58 |
| ▸ | EGLN3 | Q9H6Z9 | 1/20 | 0.55 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.55 |
| ▸ | APAF1 | O14727 | 1/20 | 0.55 |
| ▸ | CYP11B1 | P15538 | 3/20 | 0.53 |
| ▸ | CYP11B2 | P19099 | 3/20 | 0.53 |
| ▸ | TNF | P01375 | 1/20 | 0.53 |
| ▸ | TSHR | P16473 | 2/20 | 0.53 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.53 |
| ▸ | PKM | P14618 | 1/20 | 0.53 |
| ▸ | GGPS1 | O95749 | 1/20 | 0.53 |
| ▸ | FDPS | P14324 | 1/20 | 0.53 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.53 |
| ▸ | MAPT | P10636 | 1/20 | 0.51 |
| ▸ | STAT3 | P40763 | 1/20 | 0.51 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9450146 | 0.94 | TDP1 (0.62) | TDP1LMNASMN1; SMN2HTTEGLN3 | |
| SCHEMBL10130604 | 0.90 | TDP1 (0.66) | TDP1LMNASMN1; SMN2HTTEGLN3 | |
| SCHEMBL13723111 | 0.89 | TDP1 (0.64) | TDP1LMNASMN1; SMN2HTTEGLN3 | |
| SCHEMBL6174975 | 0.88 | TDP1 (0.68) | TDP1LMNASMN1; SMN2HTTEGLN3 | |
| SCHEMBL9181106 | 0.87 | TDP1 (0.62) | TDP1LMNASMN1; SMN2HTTEGLN3 | |
| SCHEMBL10894684 | 0.87 | TDP1 (0.66) | TDP1LMNASMN1; SMN2HTTEGLN3 | |
| SCHEMBL14214501 | 0.84 | TDP1 (0.62) | TDP1LMNASMN1; SMN2HTTEGLN3 | |
| SCHEMBL6442808 | 0.83 | TDP1 (1.00) | TDP1LMNASMN1; SMN2HTTEGLN3 | |
| SCHEMBL1026002 | 0.82 | APAF1 (0.67) | TDP1LMNASMN1; SMN2HTTAPAF1 | |
| SCHEMBL9320420 | 0.81 | TDP1 (0.62) | TDP1LMNASMN1; SMN2HTTEGLN3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240238473-A1 | RECOMBINANT NUCLEIC ACID MOLECULES AND THEIR USE IN WOUND HEALING | PRESIDENT AND FELLOWS OF HARVARD COLLEGE | 2024-07-18 | — | — | US | disclosed |
| US-20240238473-A1 | RECOMBINANT NUCLEIC ACID MOLECULES AND THEIR USE IN WOUND HEALING | PRESIDENT AND FELLOWS OF HARVARD COLLEGE | 2024-07-18 | — | — | US | disclosed |
| US-20230322744-A1 | COMPOUNDS AS GLP-1R AGONISTS | TERNS PHARMACEUTICALS, INC. | 2023-10-12 | — | — | US | disclosed |
| US-11771715-B2 | Circular RNA compositions and methods | ORNA THERAPEUTICS, INC. (US) | 2023-10-03 | — | — | US | disclosed |
| US-11771715-B2 | Circular RNA compositions and methods | ORNA THERAPEUTICS, INC. (US) | 2023-10-03 | — | — | US | disclosed |
| US-11766449-B2 | Circular RNA compositions and methods | ORNA THERAPEUTICS, INC. (US) | 2023-09-26 | — | — | US | disclosed |
| US-11766449-B2 | Circular RNA compositions and methods | ORNA THERAPEUTICS, INC. (US) | 2023-09-26 | — | — | US | disclosed |
| US-20230226096-A1 | CIRCULAR RNA COMPOSITIONS AND METHODS | ORNA THERAPEUTICS, INC. | 2023-07-20 | — | — | US | disclosed |
| US-20230226096-A1 | CIRCULAR RNA COMPOSITIONS AND METHODS | ORNA THERAPEUTICS, INC. | 2023-07-20 | — | — | US | disclosed |
| US-11679120-B2 | Circular RNA compositions and methods | ORNA THERAPEUTICS, INC. (US) | 2023-06-20 | — | — | US | disclosed |
| US-20130053403-A1 | NOVEL BETA 3 ADRENERGIC RECEPTOR AGONISTS | MERCK SHARP & DOHME LLC | 2013-02-28 | — | — | US | disclosed |
| CN-102084535-A | Dye-sensitized photoelectric conversion element | PECCELL TECHNOLOGIES INC | 2011-06-01 | — | — | CN | disclosed |
| US-20110041915-A1 | DYE-SENSITIZED PHOTOELECTRIC CONVERSION ELEMENT | PECCELL TECHNOLOGIES, INC. (JP) | 2011-02-24 | — | — | US | disclosed |
| EP-2276103-A1 | DYE-SENSITIZED PHOTOELECTRIC CONVERSION ELEMENT | Peccell Technologies Inc (JP) | 2011-01-19 | — | — | EP | disclosed |
| US-20080267942-A1 | BENZAZEPIN-2(1H)-ONE DERIVATIVES | PFIZER LIMITED (GB) | 2008-10-30 | — | — | US | disclosed |
| US-7393873-B2 | Arylsulfonamide derivatives | MERCK & CO., INC. (US) | 2008-07-01 | — | — | US | disclosed |
| US-20080103130-A1 | 7-hydroxy-6-{[1-methyl-3-(1,3-thiazol-5-yl)propyl]amino}-4,5,6,7-tetrahydroimidazo[4,5,1-jk][1]benzazepin-2(1H)-one; agonists at the beta-2 adrenoceptor; feed additives for livestock animals; improving meat yield or meat quality | PFIZER LIMITED (GB) | 2008-05-01 | — | — | US | disclosed |
| US-7273853-B2 | 6-11 bicyclic ketolide derivatives | ENANTA PHARMACEUTICALS, INC. (US) | 2007-09-25 | — | — | US | disclosed |
| US-20060135554-A1 | Novel compounds | ASTRAZENECA AB (SE) | 2006-06-22 | — | — | US | disclosed |
| US-7030139-B2 | Compounds | ASTRAZENECA AB (SE) | 2006-04-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130053403-A1 | NOVEL BETA 3 ADRENERGIC RECEPTOR AGONISTS | ADRB3, ADRB1, ADRB2 | TDP1 3577/4885LMNA 1572/4885SMN1; SMN2 3102/4885 |
| US-11771715-B2 | Circular RNA compositions and methods | RTCB, HNRNPA1, HNRNPAB | TDP1 2322/4885LMNA 918/4885SMN1; SMN2 341/4885 |
| US-20240238473-A1 | RECOMBINANT NUCLEIC ACID MOLECULES AND THEIR USE IN WOUND HEALING | CHI3L2, CHI3L1, FGF2 | TDP1 1891/4885LMNA 4705/4885SMN1; SMN2 4320/4885 |
| US-20060135554-A1 | Novel compounds | OPRL1, OPRK1, TRPV1 | TDP1 3487/4885LMNA 4123/4885SMN1; SMN2 446/4885 |
| US-20230322744-A1 | COMPOUNDS AS GLP-1R AGONISTS | GLP1R, GIPR, GCGR | TDP1 3083/4885LMNA 1786/4885SMN1; SMN2 1131/4885 |
| US-20080103130-A1 | 7-hydroxy-6-{[1-methyl-3-(1,3-thiazol-5-yl)propyl]amino}-4,5,6,7-tetrahydroimidazo[4,5,1-jk][1]benzazepin-2(1H)-one; agonists at the beta-2 adrenoceptor; feed additives for livestock animals; improving meat yield or meat quality | ADRB2, ADRB1, ADRA2C | TDP1 2966/4885LMNA 999/4885SMN1; SMN2 1803/4885 |
| US-20230226096-A1 | CIRCULAR RNA COMPOSITIONS AND METHODS | RTCB, HNRNPA1, HNRNPAB | TDP1 2322/4885LMNA 918/4885SMN1; SMN2 341/4885 |
| US-20080267942-A1 | BENZAZEPIN-2(1H)-ONE DERIVATIVES | ADRB2, ADRB1, ADRA2C | TDP1 4088/4885LMNA 865/4885SMN1; SMN2 2020/4885 |
| US-11679120-B2 | Circular RNA compositions and methods | RTCB, HNRNPA1, HNRNPAB | TDP1 2322/4885LMNA 918/4885SMN1; SMN2 341/4885 |
| US-11766449-B2 | Circular RNA compositions and methods | RTCB, RNGTT, HNRNPAB | TDP1 2441/4885LMNA 1053/4885SMN1; SMN2 363/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.